GB-83 is a selective, reversible PAR2 (Protease-activated receptor 2) antagonist with IC50 of 2 uM.

GB-88 is a selective, orally available PAR2 antagonist that inhibits PAR2 activated Ca(2+) release with IC50 of 2 uM.

GDC-0077 is an orally available PI3K inhibitor with potential antineoplastic activity. GDC-0077 is extracted from patent WO 2017001645 A1, formula I.

GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kinase (PI3Kalpha inhibitor).

GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3Kα and other 266 kinases.

GDC046 is a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile.

GDC-0623 is a potent, ATP-uncompetitive inhibitors of MEK1(Ki=0.13 nM, +ATP).

GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.

GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer..

GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer..

GDC-0927 Racemate is a degrader of estrogen receptor, potently inhibits ER-α activity, with an IC50 of 0.2 nM, and is used in the research of ER-related diseases.

GDC-0941 2 MeSO3H salt is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

GDC-0994 is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

GeA-69(GeA69) is a potent, selective, allosteric, cell-active PARP14 macrodomain 2 (MD2) inhibitor with Kd of 0.86 uM in ITC assays.

Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.

Gemcitabine elaidate is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.

Gemcitabine Hydrochloride (Gemzar) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively,showed potent activity against COVID-19(SARS-COV-2) with EC50 MERS-COV(1.216), SARS-COV(4.9

Gemcitabine(Gemzar) belongs to the group of medicines called antimetabolites.

Gemifloxacin mesylate (trade name Factive, Oscient Pharmaceuticals) is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.

Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2) antagonist, with IC50s of 1.7, 25 nM for human CysLT1 and CysLT2, respectively.